NCNA Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NuCana plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$19.41 |
| 52 Week Low | US$1.53 |
| Beta | 1 |
| 11 Month Change | -21.72% |
| 3 Month Change | -54.68% |
| 1 Year Change | -86.81% |
| 33 Year Change | -97.60% |
| 5 Year Change | -99.05% |
| Change since IPO | -99.62% |
Recent News & Updates
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?
Aug 21
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely
Mar 14Recent updates
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?
Aug 21Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely
Mar 14We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate
Oct 15Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation
Jul 01Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Mar 15Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Nov 30NuCana: An Intriguing 'Sum Of The Parts' Story
Sep 22NuCana GAAP EPS of -£0.07
Aug 17NuCana regains Nasdaq compliance
Jul 27NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead
Jul 13Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
May 02We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth
Jan 17NuCana: Preparing For A Critical 2022
Dec 08We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow
Sep 30NuCana: The Market Continues To Overlook Its ProTide Platform Technology
Sep 11We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth
Jun 01Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth
Feb 15How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?
Dec 22
NuCana (NCNA) Investor Presentation - Slideshow
Dec 02NuCana reports Q3 results
Nov 19Shareholder Returns
| NCNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.9% | -0.7% | -1.6% |
| 1Y | -86.8% | 19.8% | 30.8% |
Return vs Industry: NCNA underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: NCNA underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| NCNA volatility | |
|---|---|
| NCNA Average Weekly Movement | 68.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NCNA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NCNA's weekly volatility has increased from 36% to 69% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 27 | Hugh Griffith | www.nucana.com |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
NuCana plc Fundamentals Summary
| NCNA fundamental statistics | |
|---|---|
| Market cap | US$3.46m |
| Earnings (TTM) | -US$36.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NCNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NCNA income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£28.18m |
| Earnings | -UK£28.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NCNA perform over the long term?
See historical performance and comparison